Dual Energy X-ray Absorptiometry (DEXA) is a common method of testing bone density as described here.
The most widely test used to screen for osteoporosis is a bone density test (densitometry) that uses an enhanced X-ray technology called dual-energy x-ray absorptiometry (DXA or DEXA). This is NOT the same as a bone scan, which relies on a radioactive injection to help detect areas of increased bone metabolism due to fracture, infection or tumors.
During a bone density test, a low energy source is passed over the body. Information evaluated by a computer allows an estimate of bone mass. This helps the doctor get an idea of bone strength, osteoporosis and risk of fracture.
The results of a DEXA bone density test are interpreted by a radiologist and and report is sent to the doctor who ordered the test. The results will have two scores or numbers.
Your T-score compares you to a young adult of your gender with peak bone mass. Any T-score larger than -1 is considered normal. The Z-score reflects the amount of bone you have compared to other people your same size, age and gender. This number is related to percentiles. Originally, only Z-scores were calculated, but when bone density machines became commercially available beginning in the 80's, T-scores were devised because different manufacturers could not agree on a standard measurement.
Checking against previous BMD results to assess if the rate of loss has slowed may show the turnaround.. see also..
The reproducibility of DEXA scores is frequently reported at 1-2 percent. That 1-2 percent is the average, but the range of reproducibility can vary as much as 7 percent. Variations come from changes in machine reading (using the same machine), technologists who are doing the test, and slight changes and body positioning, all of which can affect the end results. The most frequent source of error in repeat tests is patient positioning. The technology is limited because BMD is a two-dimensional image of a three-dimensional object.
A few more issues related to DEXA scores are covered in a Wikipedia article which says, inter alia, “It is important for patients to get repeat BMD measurements done on the same machine each time, or at least a machine from the same manufacturer. Error between machines, or trying to convert measurments from one manufacturer's standard to another can introduce errors large enough to wipe out the sensitivity of the measurments.” https://en.wikipedia.org/wiki/Dual-energy_X-ray_absorptiometry
Other tests that are used to evaluate bone health include bone ultrasound (usually of the heel) and quantitative computed tomography (QTC) of the spine.
Osteoporosis and Th1 illness Risk factors, BMD testing and other information
My 25-DThe vitamin D metabolite widely (and erroneously) considered best indicator of vitamin D "deficiency." Inactivates the Vitamin D Nuclear Receptor. Produced by hydroxylation of vitamin D3 in the liver. is low and/or my 1,25-DPrimary biologically active vitamin D hormone. Activates the vitamin D nuclear receptor. Produced by hydroxylation of 25-D. Also known as 1,25-dihydroxycholecalciferol, 1,25-hydroxyvitamin D and calcitirol. is high. Should I be concerned about osteoporosis?
Don't I need to take a calcium supplement to prevent osteoporosis?
Don't I need Vitamin D to prevent bone loss?
It is very important not to overdo exercise.. there are a range of motion exercises within the Exercise guidelines FAQ.
A Review - Vitamin D and Calcium in Sarcoidosis (7-5-03) https://www.sarcinfo.com/calcium.htm
Epidemiological study finds a strong association between high 1,25 D levels and osteoporosis. Relationships between bone mineral density, serum vitamin D metabolites and calcium:phosphorus intake in healthy perimenopausal women. Brot C, Jorgensen N, Madsen OR, Jensen LB, Sorensen OH.
The Danish epidemiologist Brot studied 500 healthy women ( that is they were not drawn from a population with particular health issues) aged 42 to 58 and concluded that in this group bone density was strongly inversely proportional to 1,25 D levels ( that is low bone density was strongly associated with high 1,25 D levels) and only rather weakly directly proportional to 25 D levels. The sample was chosen randomly - and was not done to test the impact of any particular treatment programme. 1)
vitamin K(1) intake was not associated with effects on BMD or fracture risk. 3)
Dietary intake of folate, but not vitamin B2 or B12, is associated with increased bone mineral density 5 years after the menopause: results from a 10-year follow-up study in early postmenopausal women. 4)
When patients with an elevated level of 1,25-D are given Fosamax (or other biphosphanates), it can cause calcium deposition into the soft tissues, reduced organ function and possible osteonecrosis of the jaw (ONJ). All these meds have some effect on the immune or endocrine system and are, therefore, to be avoided.